Evidence map›Paper›PMID 24190508›Full record

ArticleArchives of virology2014

Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA.

Jens H Kuhn, Yīmíng Bào, Sina Bavari, Stephan Becker, Steven Bradfute, Kristina Brauburger, J Rodney Brister, Alexander A Bukreyev, Yíngyún Caì, Kartik Chandran and 42 more

Open access · bronzeAbstract read
In one paragraph

Article in Archives of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 75 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Ebola Virus Encodes Two microRNAs in Huh7-Infected Cells.International journal of molecular sciences · 2022
    Article
  9. Prevention of Emerging Infections in Children.Pediatric clinics of North America · 2022
    Review
  10. Article
  11. Article
  12. Mechanisms of Immune Evasion by Ebola Virus.Advances in experimental medicine and biology · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Molecular pathogenesis of viral hemorrhagic fever.Seminars in immunopathology · 2017
    Review
  20. A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors at 20 institutions in 11 countries.

Jens H KuhnIntegrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick, MD, 21702, USA, kuhnjens@mail.nih.gov.
Yīmíng Bào
Sina Bavari
Stephan Becker
Steven Bradfute
Kristina Brauburger
J Rodney Brister
Alexander A Bukreyev
Yíngyún Caì
Kartik Chandran
Robert A Davey
Olga Dolnik
John M Dye
Sven Enterlein
Jean-Paul Gonzalez
Pierre Formenty
Alexander N Freiberg
Lisa E Hensley
Thomas Hoenen
Anna N Honko
Georgy M Ignatyev
Peter B Jahrling
Karl M Johnson
Hans-Dieter Klenk
Gary Kobinger
Matthew G Lackemeyer
Eric M Leroy
Mark S Lever
Elke Mühlberger
Sergey V Netesov
Gene G Olinger
Gustavo Palacios
Jean L Patterson
Janusz T Paweska
Louise Pitt
Sheli R Radoshitzky
Elena I Ryabchikova
Erica Ollmann Saphire
Aleksandr M Shestopalov
Sophie J Smither
Nancy J Sullivan
Robert Swanepoel
Ayato Takada
Jonathan S Towner
Guido van der Groen
Viktor E Volchkov
Valentina A Volchkova
Victoria Wahl-Jensen
Travis K Warren
Kelly L Warfield
Manfred Weidmann
Stuart T Nichol
United States Army Medical Research Institute of Infectious Diseases · USNational Institutes of Health · USPhilipps University of Marburg · DEBoston University · USDefence Science and Technology Laboratory · GBIntegrated BioTherapeutics (United States) · USNational Institute of Allergy and Infectious Diseases · USNovosibirsk State University · RUTexas Biomedical Research Institute · USThe University of Texas Medical Branch at Galveston · USAlbert Einstein College of Medicine · USCenters for Disease Control and Prevention · USCentre International de Recherches Médicales de Franceville · GAHokkaido University · JPInserm · FRInstitut de Recherche pour le Développement · FRInstitute of Chemical Biology and Fundamental Medicine · RUInstituut voor Tropische Geneeskunde · BEMinistry of Health of the Russian Federation · RUNational Center for Biotechnology Information · US

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Dennis A Bente · 2011 to 2026
$208.8M
Health, Safety and Training ServicesUC7AI070083 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI LEMON, STANLEY M. · 2006 to 2010
$49.5M
Intramural NIH HHS Z99 AI999999NIAID NIH HHS HHSN272200700016INIAID NIH HHS UC7 AI070083NIAID NIH HHS UC7 AI094660World Health Organization 001
6 · The paper itself

Abstract

Specific alterations (mutations, deletions, insertions) of virus genomes are crucial for the functional characterization of their regulatory elements and their expression products, as well as a prerequisite for the creation of attenuated viruses that could serve as vaccine candidates. Virus genome tailoring can be performed either by using traditionally cloned genomes as starting materials, followed by site-directed mutagenesis, or by de novo synthesis of modified virus genomes or parts thereof. A systematic nomenclature for such recombinant viruses is necessary to set them apart from wild-type and laboratory-adapted viruses, and to improve communication and collaborations among researchers who may want to use recombinant viruses or create novel viruses based on them. A large group of filovirus experts has recently proposed nomenclatures for natural and laboratory animal-adapted filoviruses that aim to simplify the retrieval of sequence data from electronic databases. Here, this work is extended to include nomenclature for filoviruses obtained in the laboratory via reverse genetics systems. The previously developed template for natural filovirus genetic variant naming, <virus name> (<strain>/)<isolation host-suffix>/<country of sampling>/<year of sampling>/<genetic variant designation>-<isolate designation>, is retained, but we propose to adapt the type of information added to each field for cDNA clone-derived filoviruses. For instance, the full-length designation of an Ebola virus Kikwit variant rescued from a plasmid developed at the US Centers for Disease Control and Prevention could be akin to "Ebola virus H.sapiens-rec/COD/1995/Kikwit-abc1" (with the suffix "rec" identifying the recombinant nature of the virus and "abc1" being a placeholder for any meaningful isolate designator). Such a full-length designation should be used in databases and the methods section of publications. Shortened designations (such as "EBOV H.sap/COD/95/Kik-abc1") and abbreviations (such as "EBOV/Kik-abc1") could be used in the remainder of the text, depending on how critical it is to convey information contained in the full-length name. "EBOV" would suffice if only one EBOV strain/variant/isolate is addressed.

Indexed as

FiloviridaeGenome, ViralReassortant Viruses

Identifiers

PMID24190508
PMCPMC4010566
OpenAlexW1482198677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.